Emergent Biosolutions (EBS) 30.74 $EBS
Ligand (LGND) Signs Deal with Gilead for OmniAb Technology
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 10:00AM CDT
Ligand (LGND) announced that it has entered into a worldwide license agreement with Gilead (GILD) for OmniAb Technology.
EBS: 30.74 (-0.77), INVA: 11.89 (+0.13), GILD: 85.75 (-0.88), LGND: 124.92 (-3.41)
Emergent BioSolutions' Board of Directors Approves Spin-Off of Aptevo Therapeutics and Sets Record and Dividend Distribution Dates and Distribution Ratio
GlobeNewswire - Mon Jul 11, 6:00AM CDT
Emergent BioSolutions Inc. (NYSE:EBS) announced today that, on July 10, 2016, its Board of Directors approved the spin-off of Aptevo Therapeutics Inc. and declared a dividend distribution of one share of Aptevo common stock for every two shares of Emergent common stock outstanding as of the close of business on July 22, 2016, the record date for the distribution. Emergent expects to complete the distribution of Aptevo common stock to Emergent stockholders on August 1, 2016.
EBS: 30.74 (-0.77)
Shares of EBS Down 26.3% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Jul 08, 1:25PM CDT
SmarTrend identified a Downtrend for Emergent Biosolutions (NYSE:EBS) on June 16th, 2016 at $40.80. In approximately 3 weeks, Emergent Biosolutions has returned 26.25% as of today's recent price of $30.09.
EBS: 30.74 (-0.77)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Emergent Biosolutions, Inc (EBS)
PR Newswire - Fri Jul 01, 9:38AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Emergent Biosolutions, Inc. ("Emergent" or the "Company"
(NYSE: EBS). Such investors are advised to contact Peretz Bronstein or his investor relations analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.
EBS: 30.74 (-0.77)
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Investigation of Emergent Biosolutions, Inc. and Advises Investors with Losses to Contact the Firm
BusinessWire - Wed Jun 29, 4:58PM CDT
Lundin Law PC announces it is investigating claims against Emergent Biosolutions, Inc. ("Emergent" or the "Company" (NYSE: EBS) concerning possible violations of federal securities laws. The investigation is related to allegations that certain statements issued by Emergent were false and misleading and/or failed to disclose material information regarding the Company's financial performance.
EBS: 30.74 (-0.77)
SHAREHOLDER ALERT: Investigation of Emergent Biosolutions, Inc. Announced by Holzer & Holzer, LLC
BusinessWire - Tue Jun 28, 12:11PM CDT
Holzer & Holzer, LLC is investigating whether certain statements made by Emergent Biosolutions, Inc. (NYSE: EBS) regarding its business and operations complied with federal securities laws.
EBS: 30.74 (-0.77)
Emergent BioSolutions Receives BARDA Task Order Valued at Up to $21.9 Million to Develop and Manufacture a Zika Vaccine
GlobeNewswire - Mon Jun 27, 8:00AM CDT
Emergent BioSolutions Inc. (NYSE:EBS) today announced that its Center for Innovation in Advanced Development and Manufacturing (CIADM) has received a task order from the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $21.9 million to develop and manufacture three cGMP lots of a Zika vaccine for use in a Phase 1 clinical trial. Using a base vaccine candidate provided by BARDA, the company will conduct technology transfer of process materials and information, process and analytical method development, execute small-scale production runs, and perform cGMP cell banking leading to cGMP manufacture of bulk drug substance and final drug product. The task order consists of a 30-month base valued at $17.9 million and includes options that, if executed, will bring the total value to up to $21.9 million.
EBS: 30.74 (-0.77)
Downgrade Alert for Emergent Biosolutions (EBS)
Comtex SmarTrend(R) - Thu Jun 23, 3:17AM CDT
Emergent Biosolutions (NYSE:EBS) was downgraded from Outperform to Market Perform at Cowen and Company today. The stock closed yesterday at $31.33 on volume of 9.6 million shares, above average daily volume of 408,000. Emergent Biosolutions share prices have moved between a 52-week high of $44.38 and a 52-week low of $27.68 and closed yesterday at 13% above that low price at $31.33 per share. Over the last five market days, the 200-day moving average (MA) has gone up 0.3% while the 50-day MA has advanced 0.3%.
EBS: 30.74 (-0.77)
Why is Emergent BioSolutions Inc. (EBS) Down 22% Today?
Afrasiab Mian - Zacks Investment Research - Wed Jun 22, 1:36PM CDT
Emergent BioSolutions Inc. (EBS) opened down 22% on Wednesday on news that the U.S. Government issued two solicitation notices that didn???t quite live up to investors??? expectations.
EBS: 30.74 (-0.77)
Watch for Emergent Biosolutions to Potentially Rebound After Falling 21.73% Yesterday
Comtex SmarTrend(R) - Wed Jun 22, 11:52AM CDT
Emergent Biosolutions (NYSE:EBS) traded in a range yesterday that spanned from a low of $29.20 to a high of $39.21. Yesterday, the shares fell 21.7%, which took the trading range below the 3-day low of $38.86 on volume of 6.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
EBS: 30.74 (-0.77)
FDA Completes Pre-Approval Inspection of Emergent BioSolutions' Large-Scale Manufacturing Facility for BioThrax
GlobeNewswire - Tue Jun 21, 6:00AM CDT
Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has completed its Pre-Approval Inspection (PAI) of Building 55, the company's facility for large-scale manufacturing of BioThrax (Anthrax Vaccine Adsorbed). At the conclusion of the inspection, the company received a No Action Indicated decision and no Form 483 observations. Successful completion of the PAI is one of the requirements for Building 55 licensure in connection with the company's supplemental Biologics License Application (sBLA) recently accepted by the FDA. The sBLA has a Prescription Drug User Fee Act (PDUFA) target action date of August 15, 2016.
EBS: 30.74 (-0.77)
Emergent (EBS) BioThrax sBLA Accepted for FDA Review
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 8:13AM CDT
Emergent BioSolutions (EBS) announced that the FDA has accepted to review the company's sBLA for manufacturing BioThrax in Building 55.
EBS: 30.74 (-0.77), ANIP: 54.26 (-1.47), PFE: 36.31 (+0.07), BMY: 76.58 (+0.38)
FDA Accepts Emergent BioSolutions' Supplemental Biologics License Application for Large-Scale Manufacturing of BioThrax in Building 55
GlobeNewswire - Fri Jun 17, 6:00AM CDT
Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Emergent's supplemental Biologics License Application (sBLA) seeking approval of the manufacture of BioThrax (Anthrax Vaccine Adsorbed) in Building 55, the company's large-scale manufacturing facility. FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of August 15, 2016.
EBS: 30.74 (-0.77)
Emergent (EBS) BioThrax Gets Orphan Status in the U.S.
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 8:48AM CDT
Emergent (EBS) announced that BioThrax was granted Orphan Drug status in the U.S.
EBS: 30.74 (-0.77), ANIP: 54.26 (-1.47), PFE: 36.31 (+0.07), BMY: 76.58 (+0.38)
23.3% Return Seen to Date on SmarTrend Emergent Biosolutions Call (EBS)
Comtex SmarTrend(R) - Tue Jun 07, 12:22AM CDT
SmarTrend identified an Uptrend for Emergent Biosolutions (NYSE:EBS) on March 30th, 2016 at $35.86. In approximately 2 months, Emergent Biosolutions has returned 23.31% as of today's recent price of $44.22.
EBS: 30.74 (-0.77)
Uptrend Call Working As Emergent Biosolutions Stock Rises 20.3% (EBS)
Comtex SmarTrend(R) - Fri May 27, 1:22AM CDT
SmarTrend identified an Uptrend for Emergent Biosolutions (NYSE:EBS) on March 30th, 2016 at $35.86. In approximately 2 months, Emergent Biosolutions has returned 20.33% as of today's recent price of $43.15.
EBS: 30.74 (-0.77)
Typhoid Fever Global Clinical Trials Review 2016 - Key Players are Novartis AG, Emergent BioSolutions & Accelovance - Research and Markets
BusinessWire - Thu May 26, 3:52PM CDT
Research and Markets has announced the addition of the "Typhoid Fever Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
EBS: 30.74 (-0.77)
Corporate Directors From Campbell Soup, Cubic, Emergent BioSolutions, MassMutual, and Navient Become NACD Fellows in Q1 2016
GlobeNewswire - Tue May 24, 8:00AM CDT
The National Association of Corporate Directors (NACD) today announced 65 corporate directors who earned NACD Fellowship--The Gold Standard Director Credential--during the first quarter of 2016. These corporate directors serve on the boards of companies such as Campbell Soup Co., Cubic Corp., Delta Dental, Emergent BioSolutions Inc., KeyCorp, MassMutual Financial Group, Navient Corp., Otter Tail Corp., Patterson Cos. Inc., PRA Group Inc., Triple-S Management Corp., and on the corporate boards of other Fortune 100, nonprofit, and private companies.
EBS: 30.74 (-0.77), KEY: 11.56 (+0.09), GTS: 26.53 (+0.23), CUB: 40.34 (-0.39), OTTR: 33.90 (+0.23)
Emergent BioSolutions Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 3:16PM CDT
-- Q1 2016 financial performance in line with guidance
EBS: 30.74 (-0.77)
Emergent Biosolutions to Hold Annual Meeting of Stockholders Thursday May 19, 2016 at 9:00 AM Eastern; Webcast Will Be Available
GlobeNewswire - Wed May 04, 3:15PM CDT
Emergent BioSolutions Inc. (NYSE:EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 19, 2016 beginning at 9:00 AM Eastern at the Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814.
EBS: 30.74 (-0.77)
Ligand (LGND) Signs Deal with Gilead for OmniAb Technology
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 10:00AM CDT
Ligand (LGND) announced that it has entered into a worldwide license agreement with Gilead (GILD) for OmniAb Technology.
EBS: 30.74 (-0.77), INVA: 11.89 (+0.13), GILD: 85.75 (-0.88), LGND: 124.92 (-3.41)
Emergent BioSolutions' Board of Directors Approves Spin-Off of Aptevo Therapeutics and Sets Record and Dividend Distribution Dates and Distribution Ratio
GlobeNewswire - Mon Jul 11, 6:00AM CDT
Emergent BioSolutions Inc. (NYSE:EBS) announced today that, on July 10, 2016, its Board of Directors approved the spin-off of Aptevo Therapeutics Inc. and declared a dividend distribution of one share of Aptevo common stock for every two shares of Emergent common stock outstanding as of the close of business on July 22, 2016, the record date for the distribution. Emergent expects to complete the distribution of Aptevo common stock to Emergent stockholders on August 1, 2016.
EBS: 30.74 (-0.77)
Shares of EBS Down 26.3% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Jul 08, 1:25PM CDT
SmarTrend identified a Downtrend for Emergent Biosolutions (NYSE:EBS) on June 16th, 2016 at $40.80. In approximately 3 weeks, Emergent Biosolutions has returned 26.25% as of today's recent price of $30.09.
EBS: 30.74 (-0.77)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Emergent Biosolutions, Inc (EBS)
PR Newswire - Fri Jul 01, 9:38AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Emergent Biosolutions, Inc. ("Emergent" or the "Company"
(NYSE: EBS). Such investors are advised to contact Peretz Bronstein or his investor relations analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484. EBS: 30.74 (-0.77)
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Investigation of Emergent Biosolutions, Inc. and Advises Investors with Losses to Contact the Firm
BusinessWire - Wed Jun 29, 4:58PM CDT
Lundin Law PC announces it is investigating claims against Emergent Biosolutions, Inc. ("Emergent" or the "Company"
(NYSE: EBS) concerning possible violations of federal securities laws. The investigation is related to allegations that certain statements issued by Emergent were false and misleading and/or failed to disclose material information regarding the Company's financial performance. EBS: 30.74 (-0.77)
SHAREHOLDER ALERT: Investigation of Emergent Biosolutions, Inc. Announced by Holzer & Holzer, LLC
BusinessWire - Tue Jun 28, 12:11PM CDT
Holzer & Holzer, LLC is investigating whether certain statements made by Emergent Biosolutions, Inc. (NYSE: EBS) regarding its business and operations complied with federal securities laws.
EBS: 30.74 (-0.77)
Emergent BioSolutions Receives BARDA Task Order Valued at Up to $21.9 Million to Develop and Manufacture a Zika Vaccine
GlobeNewswire - Mon Jun 27, 8:00AM CDT
Emergent BioSolutions Inc. (NYSE:EBS) today announced that its Center for Innovation in Advanced Development and Manufacturing (CIADM) has received a task order from the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $21.9 million to develop and manufacture three cGMP lots of a Zika vaccine for use in a Phase 1 clinical trial. Using a base vaccine candidate provided by BARDA, the company will conduct technology transfer of process materials and information, process and analytical method development, execute small-scale production runs, and perform cGMP cell banking leading to cGMP manufacture of bulk drug substance and final drug product. The task order consists of a 30-month base valued at $17.9 million and includes options that, if executed, will bring the total value to up to $21.9 million.
EBS: 30.74 (-0.77)
Downgrade Alert for Emergent Biosolutions (EBS)
Comtex SmarTrend(R) - Thu Jun 23, 3:17AM CDT
Emergent Biosolutions (NYSE:EBS) was downgraded from Outperform to Market Perform at Cowen and Company today. The stock closed yesterday at $31.33 on volume of 9.6 million shares, above average daily volume of 408,000. Emergent Biosolutions share prices have moved between a 52-week high of $44.38 and a 52-week low of $27.68 and closed yesterday at 13% above that low price at $31.33 per share. Over the last five market days, the 200-day moving average (MA) has gone up 0.3% while the 50-day MA has advanced 0.3%.
EBS: 30.74 (-0.77)
Why is Emergent BioSolutions Inc. (EBS) Down 22% Today?
Afrasiab Mian - Zacks Investment Research - Wed Jun 22, 1:36PM CDT
Emergent BioSolutions Inc. (EBS) opened down 22% on Wednesday on news that the U.S. Government issued two solicitation notices that didn???t quite live up to investors??? expectations.
EBS: 30.74 (-0.77)
Watch for Emergent Biosolutions to Potentially Rebound After Falling 21.73% Yesterday
Comtex SmarTrend(R) - Wed Jun 22, 11:52AM CDT
Emergent Biosolutions (NYSE:EBS) traded in a range yesterday that spanned from a low of $29.20 to a high of $39.21. Yesterday, the shares fell 21.7%, which took the trading range below the 3-day low of $38.86 on volume of 6.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
EBS: 30.74 (-0.77)
FDA Completes Pre-Approval Inspection of Emergent BioSolutions' Large-Scale Manufacturing Facility for BioThrax
GlobeNewswire - Tue Jun 21, 6:00AM CDT
Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has completed its Pre-Approval Inspection (PAI) of Building 55, the company's facility for large-scale manufacturing of BioThrax (Anthrax Vaccine Adsorbed). At the conclusion of the inspection, the company received a No Action Indicated decision and no Form 483 observations. Successful completion of the PAI is one of the requirements for Building 55 licensure in connection with the company's supplemental Biologics License Application (sBLA) recently accepted by the FDA. The sBLA has a Prescription Drug User Fee Act (PDUFA) target action date of August 15, 2016.
EBS: 30.74 (-0.77)
Emergent (EBS) BioThrax sBLA Accepted for FDA Review
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 8:13AM CDT
Emergent BioSolutions (EBS) announced that the FDA has accepted to review the company's sBLA for manufacturing BioThrax in Building 55.
EBS: 30.74 (-0.77), ANIP: 54.26 (-1.47), PFE: 36.31 (+0.07), BMY: 76.58 (+0.38)
FDA Accepts Emergent BioSolutions' Supplemental Biologics License Application for Large-Scale Manufacturing of BioThrax in Building 55
GlobeNewswire - Fri Jun 17, 6:00AM CDT
Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Emergent's supplemental Biologics License Application (sBLA) seeking approval of the manufacture of BioThrax (Anthrax Vaccine Adsorbed) in Building 55, the company's large-scale manufacturing facility. FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of August 15, 2016.
EBS: 30.74 (-0.77)
Emergent (EBS) BioThrax Gets Orphan Status in the U.S.
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 8:48AM CDT
Emergent (EBS) announced that BioThrax was granted Orphan Drug status in the U.S.
EBS: 30.74 (-0.77), ANIP: 54.26 (-1.47), PFE: 36.31 (+0.07), BMY: 76.58 (+0.38)
23.3% Return Seen to Date on SmarTrend Emergent Biosolutions Call (EBS)
Comtex SmarTrend(R) - Tue Jun 07, 12:22AM CDT
SmarTrend identified an Uptrend for Emergent Biosolutions (NYSE:EBS) on March 30th, 2016 at $35.86. In approximately 2 months, Emergent Biosolutions has returned 23.31% as of today's recent price of $44.22.
EBS: 30.74 (-0.77)
Uptrend Call Working As Emergent Biosolutions Stock Rises 20.3% (EBS)
Comtex SmarTrend(R) - Fri May 27, 1:22AM CDT
SmarTrend identified an Uptrend for Emergent Biosolutions (NYSE:EBS) on March 30th, 2016 at $35.86. In approximately 2 months, Emergent Biosolutions has returned 20.33% as of today's recent price of $43.15.
EBS: 30.74 (-0.77)
Typhoid Fever Global Clinical Trials Review 2016 - Key Players are Novartis AG, Emergent BioSolutions & Accelovance - Research and Markets
BusinessWire - Thu May 26, 3:52PM CDT
Research and Markets has announced the addition of the "Typhoid Fever Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
EBS: 30.74 (-0.77)
Corporate Directors From Campbell Soup, Cubic, Emergent BioSolutions, MassMutual, and Navient Become NACD Fellows in Q1 2016
GlobeNewswire - Tue May 24, 8:00AM CDT
The National Association of Corporate Directors (NACD) today announced 65 corporate directors who earned NACD Fellowship--The Gold Standard Director Credential--during the first quarter of 2016. These corporate directors serve on the boards of companies such as Campbell Soup Co., Cubic Corp., Delta Dental, Emergent BioSolutions Inc., KeyCorp, MassMutual Financial Group, Navient Corp., Otter Tail Corp., Patterson Cos. Inc., PRA Group Inc., Triple-S Management Corp., and on the corporate boards of other Fortune 100, nonprofit, and private companies.
EBS: 30.74 (-0.77), KEY: 11.56 (+0.09), GTS: 26.53 (+0.23), CUB: 40.34 (-0.39), OTTR: 33.90 (+0.23)
Emergent BioSolutions Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 3:16PM CDT
-- Q1 2016 financial performance in line with guidance
EBS: 30.74 (-0.77)
Emergent Biosolutions to Hold Annual Meeting of Stockholders Thursday May 19, 2016 at 9:00 AM Eastern; Webcast Will Be Available
GlobeNewswire - Wed May 04, 3:15PM CDT
Emergent BioSolutions Inc. (NYSE:EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 19, 2016 beginning at 9:00 AM Eastern at the Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814.
EBS: 30.74 (-0.77)
